ganaplacide: Clinical Trials

8 completed, 1 recruiting. 5 Phase 2, 4 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	5	Completed 4, Recruiting 1
Phase 1	4	Completed 4

Follow ganaplacide: new trials by email Literature Review of ganaplacide trials Research Report on ganaplacide

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2) KAE609, SoC (Coartem), KLU156 - Uncomplicated Plasmodium Falciparum Malaria	Phase 2	Recruiting	Novartis Pharmaceuticals	120	2026-02-12	2026-10-15
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2) KAE609, SoC (Coartem), KLU156 - Uncomplicated Plasmodium Falciparum Malaria	Phase 2	Completed	Novartis Pharmaceuticals	60	2024-01-23	2026-05-07
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz Ganaplacide, Lumefantrine, Efavirenz - Malaria	Phase 1	Completed	Novartis Pharmaceuticals	14	2022-04-28	2023-01-12
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir Midazolam, Repaglinide, Dextromethorphan - Malaria	Phase 1	Completed	Novartis Pharmaceuticals	48	2022-03-09	2022-11-04
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole Ganaplacide, Lumefantrine, Itraconazole - Malaria	Phase 1	Completed	Novartis Pharmaceuticals	19	2021-11-18	2022-10-28
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria KAF156, LUM-SDF, Coartem - Uncomplicated Plasmodium Falciparum Malaria	Phase 2	Completed	Novartis Pharmaceuticals	295	2021-02-16	2026-05-07
Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria KAF156, Coartem, Lumefantrine Solid Dispersion Formulation - Acute Uncomplicated Plasmodium Falciparum Malaria	Phase 2	Completed	Novartis Pharmaceuticals	524	2017-08-02	2022-02-10
Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model KAF156, Placebo - Malaria	Phase 1	Completed	Novartis Pharmaceuticals	86	2014-09-15	2019-08-28
Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection KAF156 - Malaria	Phase 2	Completed	Novartis Pharmaceuticals	43	2013-03-01	2018-06-07

Conditions studied

Malaria (5)  ·  Malaria, Falciparum (3)  ·  Acute malaria (1)

Sponsors

Novartis Pharmaceuticals (9)

Countries

Gabon (4)  ·  Burkina Faso (3)  ·  Côte d’Ivoire (3)  ·  Kenya (3)  ·  United Kingdom (3)  ·  Mali (2)  ·  Thailand (2)  ·  Uganda (2)  ·  Vietnam (2)  ·  Ghana (1)  ·  India (1)  ·  Mozambique (1)  ·  Republic of the Congo (1)  ·  Rwanda (1)  ·  United States (1)

Results publications

PMID 37327809, PMID 27653565, PMID 32644127, PMID 39344281, PMID 41121745